Tarsus Pharmaceuticals (NASDAQ:TARS) Posts Earnings Results, Beats Expectations By $0.08 EPS

Tarsus Pharmaceuticals (NASDAQ:TARS) issued its quarterly earnings results on Tuesday. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.08, Zacks reports. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The business had revenue of $66.41 million during the quarter, compared to the consensus estimate of $58.80 million.

Tarsus Pharmaceuticals Stock Down 9.3 %

Shares of NASDAQ:TARS opened at $41.29 on Wednesday. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. The firm has a market cap of $1.58 billion, a P/E ratio of -10.84 and a beta of 1.01. Tarsus Pharmaceuticals has a 12 month low of $20.08 and a 12 month high of $57.28. The company’s 50-day moving average price is $51.51 and its two-hundred day moving average price is $43.00.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on TARS. Guggenheim reissued a “buy” rating on shares of Tarsus Pharmaceuticals in a research note on Monday. The Goldman Sachs Group boosted their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research note on Friday, November 15th. Barclays lowered their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research note on Wednesday. Oppenheimer boosted their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $73.00 price target on shares of Tarsus Pharmaceuticals in a report on Wednesday. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $58.00.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.